Evidence Hub

Metformin in patients with polycystic ovary syndrome on the endocrine and metabolic effects

Gan Zhengq

Clinical Medicine, 2008

Abstract

Objective To investigate the endocrine and metabolic effects of metformin on patients with polycystic ovary syndrome(PCOS)and assess metformin in the treatment of patients with PCOS.Methods Thirty-six cases of PCOS were treated with metformin for 12 weeks(before treatment for group A,after treatment as group B),the choice of the same period in the normal menstrual cycle of women 26 cases for the control group(group C).Body mass index(BMI),sex hormone,blood lipids,fasting glucose,fasting insulin(FINS)were determined and insulin sensitivity index(ISI) were computed.Results ①To compared with the group C,the levels of BMI,triglyceride(TG),low-density lipoprotein-elevated cholesterol(LDL-C),FINS,luteinizing hormone(LH),LH/follicle-stimulating hormone(FSH),testosterone(T) were higher(P0.05),ISI were lower(P0.01)in group A;②To compared with the group A,the levels of BMI,TG,LDL-C,FINS,LH,LH/FSH,T were lower(P0.05),ISI were higher(P0.01) in group B.Conclusion Metformin can correct the endocrine and metabolic disorders in patients with PCOS,is an important means of PCOS.

Read the paper

Related studies

Go deeper in Evidence Hub

Evidence Hub adds a study data sheet (design, sample size, evidence level, key numbers), an AI summary and a chat grounded in the paper's text.

Open this study Sign up free